Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

American Journal of Cardiology

Volumn 103, Issue 5, 2009, Pages 577-582

  Tikkanen, Matti J ^a   Holme, Ingar ^b   Cater, Nilo B ^c   Szarek, Michael ^c   Faergeman, Ole ^d   Kastelein, John J P ^e   Olsson, Anders G ^f   Larsen, Mogens Lytken ^d   Lindahl, Christina ^g   Pedersen, Terje R ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c PFIZER INC   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g Pfizer Sweden   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYOPATHY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 60249085143     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.10.029     Document Type: Article

References (10)

1. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
2. Hansson L., Hedner T., and Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1 (1992) 113-119
3. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
4. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
5. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., and Palmer G. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering Study. Am J Cardiol 94 (2004) 720-724
6. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
7. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H., and CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet 364 (2004) 685-696
8. Wenger N.K., Lewis S.J., Herrington D.M., Bittner V., and Welty F.K. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 147 (2007) 1-9
9. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
10. Furberg C.D., and Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2 (2001) 205-207